Previous close | 0.0150 |
Open | 0.0160 |
Bid | 0.0160 x 0 |
Ask | 0.0170 x 0 |
Day's range | 0.0150 - 0.0170 |
52-week range | 0.0040 - 0.0260 |
Volume | 31,567,500 |
Avg. volume | 30,272,943 |
Market cap | 72.547M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0050 |
Earnings date | 06 Aug 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).